Salud financiera de hoja de balance de Probi

Salud financiera controles de criterios 6/6

Probi tiene unos fondos propios totales de SEK1.5B y una deuda total de SEK0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son SEK1.6B y SEK138.5M respectivamente. Probi El EBIT de la empresa es de SEK9.0M, por lo que su ratio de cobertura de intereses es de -2. Su tesorería e inversiones a corto plazo ascienden a SEK300.8M.

Información clave

Ratio deuda-patrimonio

kr0

Deuda

Ratio de cobertura de intereses	-1.9x
Efectivo	kr329.65m
Patrimonio	kr1.37b
Total pasivo	kr121.36m
Activos totales	kr1.49b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 19% Below Its Share Price

May 05

Is Probi AB (publ)'s (STO:PROB) Recent Price Movement Underpinned By Its Weak Fundamentals?

Mar 05

Here's Why I Think Probi (STO:PROB) Might Deserve Your Attention Today

Feb 15

Here's What Probi AB (publ)'s (STO:PROB) Shareholder Ownership Structure Looks Like

Jan 29

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 20% Below Its Share Price

Jan 11

Have Insiders Been Buying Probi AB (publ) (STO:PROB) Shares?

Dec 22

Has Probi AB (publ)'s (STO:PROB) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Dec 03

Análisis de la situación financiera

Pasivos a corto plazo: PROBLos activos a corto plazo (SEK564.4M) de la empresa superan a sus pasivos a corto plazo (SEK85.7M).

Pasivo a largo plazo: PROBLos activos a corto plazo (SEK564.4M) superan a sus pasivos a largo plazo (SEK52.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: PROB está libre de deudas.

Reducción de la deuda: PROB no tiene deuda en comparación con hace 5 años, cuando su ratio deuda/fondos propios era de 11.5%.

Cobertura de la deuda: PROB no tiene deuda, por lo que no necesita cubrirse con flujo de caja operativo.

Cobertura de intereses: PROB no tiene deuda, por lo que la cobertura del pago de intereses no es motivo de preocupación.

Hoja de balance

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de Probi

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Now 22% undervalued

Now 22% undervalued

Full year 2023 earnings: EPS exceeds analyst expectations

Now 21% undervalued

Dividend of kr1.30 announced

Now 21% undervalued after recent price drop

Probi AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Full year 2023 earnings: EPS exceeds analyst expectations

Probi AB (Publ) Proposes Dividend for the Fiscal Year 2023

Probi AB (publ) to Report Q3, 2024 Results on Oct 22, 2024

Probi AB (publ), Annual General Meeting, May 07, 2024

Third quarter 2023 earnings released: EPS: kr0.56 (vs kr1.09 in 3Q 2022)

Probi AB (Publ) Appoints Per Lindblad as New CFO, Effective from 1st of November, 2023

Probi Launches Two New Concepts Together with Clasado Biosciences at Supply Side West

Second quarter 2023 earnings released: kr0.55 loss per share (vs kr1.75 profit in 2Q 2022)

Probi AB (Publ) Announces Resignation of Henrik Lundkvist as Chief Financial Officer

Insufficient new directors

Upcoming dividend of kr1.30 per share at 0.7% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (publ) to Report Fiscal Year 2022 Final Results on Apr 04, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (Publ) Proposes Dividend for the 2022 Financial Year, Payable on May 11, 2023

Now 24% undervalued after recent price drop

Now 20% undervalued after recent price drop

Probi AB (publ) to Report Q2, 2023 Results on Jul 18, 2023

Now 21% undervalued after recent price drop

Probi AB (publ) Announces Management Changes

Now 25% undervalued after recent price drop

Probi Probiotics Reduce Gut Problems in Connection with Cancer Radiotherapy

Now 21% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Probi AB (Publ) Approves Dividend for the Financial Year 2021

Chief Executive Officer recently bought kr409k worth of stock

Upcoming dividend of kr1.30 per share

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend, Payable on 12 May 2022

Now 23% undervalued after recent price drop

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend for the Year 2021

Third quarter 2021 earnings released: EPS kr1.62 (vs kr2.91 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Should You Be Adding Probi (STO:PROB) To Your Watchlist Today?

Estimating The Intrinsic Value Of Probi AB (publ) (STO:PROB)

Consensus EPS estimates fall to kr8.37

Second quarter 2021 earnings released: EPS kr1.39 (vs kr2.37 in 2Q 2020)

Investor sentiment improved over the past week

Is Now The Time To Put Probi (STO:PROB) On Your Watchlist?

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 19% Below Its Share Price

Upcoming dividend of kr1.10 per share

Price target increased to kr505

Full year 2020 earnings released: EPS kr8.14 (vs kr7.54 in FY 2019)

Probi AB (publ) Announces Three Years Collaboration with La Trobe University

Is Probi AB (publ)'s (STO:PROB) Recent Price Movement Underpinned By Its Weak Fundamentals?

Probi and Perrigo Sign Extensive Pan-European Agreement for Launch of Probiotic Concepts

Here's Why I Think Probi (STO:PROB) Might Deserve Your Attention Today

Full year 2020 earnings released: EPS kr8.14 (vs kr7.54 in FY 2019)

Price target raised to kr455

Revenue beats expectations, earnings disappoint

Here's What Probi AB (publ)'s (STO:PROB) Shareholder Ownership Structure Looks Like

New 90-day high: kr483

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 20% Below Its Share Price

New 90-day high: kr443

Have Insiders Been Buying Probi AB (publ) (STO:PROB) Shares?

New 90-day high: kr436

Has Probi AB (publ)'s (STO:PROB) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Market bids up stock over the past week

New 90-day high: kr401

Third quarter earnings released